Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis

MLA

Himmelbauer, Martin K., et al. “Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.” Journal of Medicinal Chemistry, vol. 67, no. 10, May 2024, pp. 8122–40. EBSCOhost, https://doi.org/10.1021/acs.jmedchem.4c00220.

APA

Himmelbauer, M. K., Bajrami, B., Basile, R., Capacci, A., Chen, T., Choi, C. K., Gilfillan, R., Gonzalez-Lopez de Turiso, F., Gu, C., Hoemberger, M., Johnson, D. S., Jones, J. H., Kadakia, E., Kirkland, M., Lin, E. Y., Liu, Y., Ma, B., Magee, T., Mantena, S., … Hopkins, B. T. (2024). Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry, 67(10), 8122–8140. https://doi.org/10.1021/acs.jmedchem.4c00220

Chicago

Himmelbauer, Martin K., Bekim Bajrami, Rebecca Basile, Andrew Capacci, TeYu Chen, Colin K. Choi, Rab Gilfillan, et al. 2024. “Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.” Journal of Medicinal Chemistry 67 (10): 8122–40. doi:10.1021/acs.jmedchem.4c00220.